Pulmonary dysplasia, Denys-Drash syndrome and Wilms tumor 1 gene mutation in twins

2001 ◽  
Vol 16 (3) ◽  
pp. 227-231 ◽  
Author(s):  
Vikas R. Dharnidharka ◽  
E. Cristy Ruteshouser ◽  
Seymour Rosen ◽  
Harry Kozakewich ◽  
H. William Harris Jr. ◽  
...  
Keyword(s):  
Gene Mutation ◽  
Wilms Tumor ◽  
Wilms Tumor 1 ◽  
Drash Syndrome

A novel Wilms’ tumor 1 gene mutation in a child with severe renal dysfunction and persistent renal blastema

2008 ◽  
Vol 23 (9) ◽  
pp. 1445-1453 ◽  
Author(s):  
Nicole Wagner ◽  
Kay-Dietrich Wagner ◽  
Mickael Afanetti ◽  
Fabien Nevo ◽  
Corinne Antignac ◽  
...  
Keyword(s):  
Renal Dysfunction ◽  
Gene Mutation ◽  
Wilms Tumor ◽  
Wilms Tumor 1 ◽  
Severe Renal Dysfunction

scholarly journals Dendritic cell–based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma

2015 ◽  
Vol 123 (4) ◽  
pp. 989-997 ◽  
Author(s):  
Keiichi Sakai ◽  
Shigetaka Shimodaira ◽  
Shinya Maejima ◽  
Nobuyuki Udagawa ◽  
Kenji Sano ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Malignant Glioma ◽  
Stable Disease ◽  
Wilms Tumor ◽  
Malignant Gliomas ◽  
Tumor Lysate ◽  
Dc Vaccine ◽  
Pulsed Dc ◽  
Wilms Tumor 1 ◽  
Vaccination Therapy

OBJECT Dendritic cell (DC)-based vaccination is considered a potentially effective therapy against advanced cancer. The authors conducted a Phase I study to investigate the safety and immunomonitoring of Wilms’ tumor 1 (WT1)-pulsed DC vaccination therapy for patients with relapsed malignant glioma. METHODS WT1-pulsed and/or autologous tumor lysate-pulsed DC vaccination therapy was performed in patients with relapsed malignant gliomas. Approximately 1 × 107 to 2 × 107 pulsed DCs loaded with WT1 peptide antigen and/or tumor lysate were intradermally injected into the axillary areas with OK-432, a streptococcal preparation, at 2-week intervals for at least 5–7 sessions (1 course) during an individual chemotherapy regimen. RESULTS Ten patients (3 men, 7 women; age range 24–64 years [median 39 years]) with the following tumors were enrolled: glioblastoma (6), anaplastic astrocytoma (2), anaplastic oligoastrocytoma (1), and anaplastic oligodendroglioma (1). Modified WT1 peptide–pulsed DC vaccine was administered to 7 patients, tumor lysate-pulsed DC vaccine to 2 patients, and both tumor lysate–pulsed and WT1-pulsed DC vaccine to 1 patient. The clinical response was stable disease in 5 patients with WT1-pulsed DC vaccination. In 2 of 5 patients with stable disease, neurological findings improved, and MR images showed tumor shrinkage. No serious adverse events occurred except Grade 1–2 erythema at the injection sites. WT1 tetramer analysis detected WT1-reactive cytotoxic T cells after vaccination in patients treated with WT1-pulsed therapy. Positivity for skin reaction at the injection sites was 80% (8 of 10 patients) after the first session, and positivity remained for these 8 patients after the final session. CONCLUSIONS This study of WT1-pulsed DC vaccination therapy demonstrated safety, immunogenicity, and feasibility in the management of relapsed malignant gliomas.

scholarly journals A novel WT1 gene mutation in a chinese girl with denys‐drash syndrome

2021 ◽  
Author(s):  
Faliang Wang ◽  
Jiabin Cai ◽  
Jinhu Wang ◽  
Min He ◽  
Junqing Mao ◽  
...  
Keyword(s):  
Gene Mutation ◽  
Wt1 Gene ◽  
Chinese Girl ◽  
Drash Syndrome

scholarly journals Wilms’ tumor 1 antigen immunoreactivity in epithelial ovarian cancer — diagnostic and prognostic value

2020 ◽  
Vol 58 (3) ◽  
pp. 198-207
Author(s):  
Elżbieta Zarychta ◽  
Katarzyna Lepinay ◽  
Sebastian Szubert ◽  
Jakub Jozwicki ◽  
Jan Misiak ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Prognostic Value ◽  
Wilms Tumor ◽  
Cancer Diagnostic ◽  
Wilms Tumor 1 ◽  
Diagnostic And Prognostic Value
Sign in / Sign up

Export Citation Format

Share Document